IL-4 Licenses B Cell Activation Through Cholesterol Synthesis

Holly R. Steach, Autumn G. York, Mathias Skadow, Shuting Chen, Jun Zhao, Kevin J. Williams, Quan Zhou, Weu-Yuan Hsieh, J. Richard Brewer, Rihao Qu, Justin A. Shyer, Christian C. D. Harman, Esen Sefik, Walter K. Mowell, Will Bailis, Can Cui, Yuval Kluger, Steven J. Bensinger, Joe Craft, Richard A. FlavellbioRxiv 2024 · DOI

TL;DR

This paper reveals that the cytokine IL-4 promotes B cell activation and proliferation by upregulating cholesterol synthesis, a crucial metabolic rewiring that allows B cells to overcome nutrient limitations. This finding sheds light on a previously unknown mechanism by which IL-4 acts as a B cell growth factor, impacting our understanding of immune responses and potentially informing strategies for vaccine development and treatment of autoimmune diseases.

What Problem Does This Paper Address?

Lymphocyte activation, particularly B cell activation, is a complex process that requires more than just antigen recognition. It necessitates "second signals," often provided by cytokines like IL-4, to fully engage proliferation and differentiation. While IL-4 is known to be a potent B cell co-mitogen, the precise molecular mechanisms by which it supports B cell growth have remained largely elusive. The authors aim to unravel how IL-4 signaling translates into enhanced B cell proliferation, especially in conditions where external nutrient availability might be limiting, a scenario relevant to the crowded microenvironments of secondary lymphoid tissues during an immune response.

Methods

The researchers employed a multi-pronged approach:

  • Single-cell RNA sequencing (scRNAseq): Used to profile gene expression in B cells during an early antiviral immune response, allowing for the identification of transcriptional programs associated with activation and IL-4 signaling.
  • Trajectory Inference (Monocle): Applied to scRNAseq data to reconstruct the developmental path of B cells from a quiescent to an activated state, enabling the temporal mapping of gene expression changes.
  • Quantitative PCR (qPCR): Used to validate gene expression findings from RNA sequencing.
  • In vitro cell culture: B cells were cultured under various conditions, including lipid-deprived media, with or without IL-4 or exogenous cholesterol, to assess the impact on proliferation.
  • Gas Chromatography-Mass Spectrometry (GC-MS) with 13C-stable isotope labeling: Employed to precisely measure the synthesis of cholesterol from glucose-derived precursors.
  • Flow Cytometry: Used to analyze cell cycle status (Ki-67 and 7-AAD staining), ER expansion (ER-Tracker Green), and mitochondrial mass (MitoTracker Green).
  • Western Blotting: To assess protein phosphorylation, specifically of S6 kinase, a downstream target of mTORC1 signaling.
  • Genetic Manipulation: Creation of conditional knockout mice (Mb1-Cre Srebf2 flox/flox) to study the role of SREBP2 in IL-4-mediated B cell activation.

Datasets

The study utilized scRNAseq data generated from murine B cells isolated from mediastinal lymph nodes of mice infected with PR8 influenza virus. Additionally, bulk RNA sequencing was performed on IL-4 stimulated B cells. No new benchmark datasets were introduced.

Key Insights and Ideas

  • IL-4 Orchestrates Cholesterol Synthesis: The most striking finding is that IL-4 signaling directly upregulates the cholesterol biosynthetic pathway in B cells during an early antiviral response. This is a novel mechanism for IL-4's co-mitogenic activity.
  • Cholesterol is Essential for B Cell Cycle Progression: Cholesterol is not just a structural component but a critical signaling molecule that licenses B cells to exit quiescence (G0) and enter the cell cycle (G1). This is a previously unrecognized role for cholesterol in immune cell activation.
  • IL-4 Circumvents External Lipid Dependence: IL-4 enables B cells to proliferate even in the absence of external lipids by boosting their endogenous cholesterol production. This highlights IL-4's role in making B cells resilient to nutrient scarcity.
  • SREBP2 is the Key Transcription Factor: The study identifies SREBP2, a master regulator of cholesterol synthesis, as a crucial downstream target of IL-4 signaling, mediating the observed upregulation of cholesterol synthesis genes.
  • ER Expansion is Cholesterol-Dependent: Cholesterol availability is directly linked to the expansion of the endoplasmic reticulum (ER), which is a prerequisite for B cell proliferation. This suggests a direct link between lipid metabolism and organelle biogenesis in immune cell activation.

Key Results

  • scRNAseq analysis revealed a strong correlation between IL-4 signature genes and the upregulation of cholesterol synthesis genes (e.g., Sqle, Hmgcr, Mvk) and downregulation of cholesterol efflux genes (e.g., Abca1, Apoe) during early B cell activation.
  • In vitro experiments demonstrated that lipid-deprived B cells failed to proliferate but this defect was rescued by IL-4 or exogenous cholesterol.
  • Treatment with statins (cholesterol synthesis inhibitors) blocked IL-4's ability to rescue proliferation in lipid-deprived cells, confirming the necessity of IL-4-induced cholesterol synthesis.
  • GC-MS with 13C-labeling showed a significant increase in both total and actively synthesized cholesterol in IL-4 treated B cells.
  • B cells deficient in SREBP2 (Mb1-Cre Srebf2 flox/flox mice) were insensitive to IL-4-induced proliferation in minimal media, with partial rescue by exogenous cholesterol.
  • Cholesterol availability was shown to be critical for ER expansion, which in turn was necessary for B cell progression from G0 to G1 and subsequent proliferation.

Limitations and Future Work

  • STAT6-SREBP2 Link: While STAT6 is identified as a downstream transcription factor of IL-4, the precise molecular mechanism by which STAT6 engages SREBP2 to coordinate transcriptional changes remains unclear and warrants further investigation.
  • Cholesterol Sensing Mechanisms: The study suggests that immune cells sense actively synthesized cholesterol in the ER, but the specific sensing mechanisms and downstream signaling components involved are not fully elucidated.
  • Inter-organellar Crosstalk: The role of inter-organellar communication in licensing cell cycle entry and proliferation, particularly in relation to ER-nuclear signaling, is an open area for future research.
  • Statin Controversy: The paper acknowledges the controversial findings regarding statin treatment and humoral immunity in human patients, suggesting that their work isolates a B cell-intrinsic role for statin immune inhibition, which could help clarify these discrepancies.
  • Broader Implications: The authors suggest that understanding this IL-4/cholesterol axis could inform vaccine strategies that rely on robust humoral immunity, especially in contexts where statin use might be a confounding factor.

Summary updated

Abstract

ABSTRACT Lymphocyte activation involves a transition from quiescence and associated catabolic metabolism to a metabolic state with noted similarities to cancer cells such as heavy reliance on aerobic glycolysis for energy demands and increased nutrient requirements for biomass accumulation and cell division 1–3 . Following antigen receptor ligation, lymphocytes require spatiotemporally distinct “second signals”. These include costimulatory receptor or cytokine signaling, which engage discrete programs that often involve remodeling of organelles and increased nutrient uptake or synthesis to meet changing biochemical demands 4–6 . One such signaling molecule, IL-4, is a highly pleiotropic cytokine that was first identified as a B cell co-mitogen over 30 years ago 7 . However, how IL-4 signaling mechanistically supports B cell proliferation is incompletely understood. Here, using single cell RNA sequencing we find that the cholesterol biosynthetic program is transcriptionally upregulated following IL-4 signaling during the early B cell response to influenza virus infection, and is required for B cell activation in vivo . By limiting lipid availability in vitro , we determine cholesterol to be essential for B cells to expand their endoplasmic reticulum, progress through cell cycle, and proliferate. In sum, we demonstrate that the well-known ability of IL-4 to act as a B cell growth factor is through a previously unknown rewiring of specific lipid anabolic programs, relieving sensitivity of cells to environmental nutrient availability.
BibTeX
@misc{steach2024il,
  author = {Holly R. Steach and Autumn G. York and Mathias Skadow and Shuting Chen and Jun Zhao and Kevin J. Williams and Quan Zhou and Weu-Yuan Hsieh and J. Richard Brewer and Rihao Qu and Justin A. Shyer and Christian C. D. Harman and Esen Sefik and Walter K. Mowell and Will Bailis and Can Cui and Yuval Kluger and Steven J. Bensinger and Joe Craft and Richard A. Flavell},
  title = {{IL-4 Licenses B Cell Activation Through Cholesterol Synthesis}},
  year = {2024},
  doi = {10.1101/2024.05.13.593964},
  howpublished = {bioRxiv},
}
Figure